Epigenomics Inks Licensing Deals with DxS, OncoMethylome Sciences | GenomeWeb
NEW YORK (GenomeWeb News) – Epigenomics said today that it has signed two separate licensing agreements with molecular diagnostics firms DxS and OncoMethylome Sciences.
 
Under its cross-licensing deal with DxS, Epigenomics received worldwide, non-exclusive rights to DxS’ Scorpions technology for use in R&D and research kits. It also received an option to expand the license to include in vitro diagnostic applications.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.